非小細胞性肺がん(Non-Small Cell Lung Cancer):治療薬市場動向2015(市場規模、APIメーカー動向、上市品、フェーズ3治験)

◆英語タイトル:Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
◆商品コード:DIIR2015103
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:75以上
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s, “Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Non-Small Cell Lung Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Non-Small Cell Lung Cancer. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Non-Small Cell Lung Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturersacross the globe coveringDrug Master FilingsofUS, Europe and API Manufacturers in Asia specifically China and India. The researchanalysis also presents the global sales forecasts data till 2016.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


SCOPE:
• A snapshot of the global Market therapeutics scenario for Non-Small Cell Lung Cancer.
• A review of the marketed products under prescription for Non-Small Cell Lung Cancer, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Non-Small Cell Lung Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Non-Small Cell Lung Cancer drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Non-Small Cell Lung Cancer drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Non-Small Cell Lung Cancer drugs.
• Coverage of Non-Small Cell Lung Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2012-2016.

【レポートの目次】

Table of Contents
Indication Overview
Marketed Drugs
Marketed Details of Drugs by Application Type
Marketed Details of Drugs (NDA) by Marketing Status
Marketed Details of Drugs by Patent Expiration Timeline
Active Pharmaceutical Ingredient (API) Manufacturers Assessment
API Manufacturers by United States Drug Master File (US DMF) Status
API Manufacturers by US DMF Status (Drug Specific)
API Manufacturers in Europe by Country
API Manufacturers in India by State
API Manufacturers in China by Province
Marketed Details of Approved Drugs by Geography
Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
API Manufacturers by US DMF Status (Drug Specific)
Drugs Market Data and Forecasted Sales Figure (2012-2016)
Marketed Drugs for Non-Small Cell Lung Cancer
Drug Name
Drug Description
Global Active Pharmaceutical Manufacturers for Drug
Approval Status of Drug
Patent and Exclusivity Details for Drug
Company Profile and Financials
Phase III Drugs for Non-Small Cell Lung Cancer
United States Drug Master File (DMF)
Discontinued Drugs for Non-Small Cell Lung Cancer
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015
Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2015
Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015
Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, Europe by Country, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, India by State, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, China by Province, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers by Geography 2015
Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015
Non-Small Cell Lung Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD)
API Manufacturers for Drug, 2015
Phase III Drugs for Non-Small Cell Lung Cancer, 2015
Discontinued Drugs for Non-Small Cell Lung Cancer, 2015


List of Figures
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015
Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015
Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2015
Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015
Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, Europe by Country, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, India by State, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers, China by Province, 2015
Non-Small Cell Lung Cancer Drugs, API Manufacturers by Geography 2015
Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015
Non-Small Cell Lung Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2015


【レポートのキーワード】

非小細胞性肺がん(Non-Small Cell Lung Cancer)、医薬品、治療薬、市場規模、販売量、医薬品有効成分(API)メーカー、治験、上市品

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非小細胞性肺がん(Non-Small Cell Lung Cancer):治療薬市場動向2015(市場規模、APIメーカー動向、上市品、フェーズ3治験)(Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆